Description

Natera Unlocks Broader Signatera Adoption With FDA, PMDA And NCCN Milestones!

Natera reported its second quarter of 2026 results marked by record test volume, strong revenue growth, and continued progress across its key business segments: oncology, women’s health, and organ health. The company processed approximately 1.04 million tests during the quarter, exceeding the one million mark for the second consecutive quarter and setting a new company record. Oncology volumes saw notable expansion, with 283,000 clinical minimal residual disease (MRD) units processed, reflecting a year-over-year increase of about 56% and a sequential increase of 34,000 units from Q1, driven by regulatory approvals, guideline endorsements, and commercial team effectiveness. Natera achieved significant oncology milestones including U.S. FDA approval and Japanese PMDA approval of Signatera as a companion diagnostic for muscle-invasive bladder cancer and colorectal cancer respectively. Additionally, the National Comprehensive Cancer Network (NCCN) issued a Category 1 recommendation supporting Signatera-guided adjuvant therapy in bladder cancer, enhancing adoption potential.